|1.||Lapchak, Paul A: 7 articles (03/2011 - 05/2002)|
|2.||Ashwood, Tim: 7 articles (06/2008 - 12/2003)|
|3.||Green, A Richard: 7 articles (02/2006 - 11/2002)|
|4.||Nilsson, Dag: 6 articles (12/2008 - 09/2006)|
|5.||Cheng, Yi-Fang: 6 articles (12/2008 - 01/2005)|
|6.||Lees, Kennedy R: 6 articles (06/2008 - 01/2005)|
|7.||Shuaib, Ashfaq: 6 articles (06/2008 - 02/2006)|
|8.||Zivin, Justin A: 6 articles (02/2007 - 05/2002)|
|9.||Green, A R: 5 articles (12/2009 - 01/2001)|
|10.||Diener, Hans-Christoph: 5 articles (06/2008 - 02/2006)|
03/01/2006 - "A recent analysis of one of the Phase III trials showed a statistically significant reduction in the primary outcome of disability after acute stroke in patients who received NXY-059 compared with placebo. "
02/09/2006 - "Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke. "
02/09/2006 - "The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. "
05/16/2003 - "NXY-059 was the only compound to produce a major, statistically significant improvement in the motor deficit induced by the stroke. "
06/01/2012 - "The nitrone-based compound NXY-059, which is the first drug to reach clinical trials for the treatment of acute ischemic stroke, has provided promise for the development of more robust pharmacological agents. "
|2.||Brain Ischemia (Cerebral Ischemia)
10/01/2008 - "We conducted a systematic review and stratified meta-analysis of published studies describing the efficacy of NXY-059 in experimental focal cerebral ischemia. "
08/03/2001 - "This study was designed to determine the effect of NXY-059 in a rodent model of permanent focal cerebral ischemia. "
08/03/2001 - "A recent study has demonstrated that NXY-059, a novel free radical trapping nitrone compound, has a neuroprotective effect against transient focal cerebral ischemia. "
01/01/2001 - "NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species."
07/01/1999 - "Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat."
03/01/2001 - "NXY-059 has neuroprotective efficacy when given 5 hours after onset of transient focal ischemia in the rat. "
11/15/2002 - "A recent in vivo study suggested that NXY-059 had poor brain uptake in a transient ischemia model. "
02/09/2006 - "Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia."
11/15/2002 - "In conclusion, it is possible that the increase in blood-brain barrier permeability of [14C]NXY-059 which occurs during prolonged ischemia in vitro reflects a change which may be of importance to the neuroprotective effects of this nitrone free radical trapping agent."
09/01/2003 - "NXY-059 has substantial protective effects when administered immediately after the onset of ischemia in a primate model of stroke. "
08/01/2007 - "The baseline hemorrhage volume was 22.4+/-20.1 mL in the NXY-059 group and 23.3+/-22.8 mL in the placebo group (mean+/-SD). "
06/01/2002 - "Thus, we determined the effects of NXY-059G, a generic form of NXY-059, on hemorrhage and infarct rate and volume when administered alone or in combination with tPA. "
03/01/2001 - "Treatment with NXY-059 significantly reduced the neutrophil infiltrate observed 48 h post-hemorrhage in the vicinity of the hematoma, and the number of TUNEL-positive cells 48 h post-hemorrhage at the hematoma margin. "
06/01/2008 - "Among patients treated with alteplase, there was no decrease in rates of symptomatic or asymptomatic hemorrhage associated with NXY-059 treatment versus placebo. "
08/09/2007 - "Among patients treated with alteplase, there was no difference between the NXY-059 group and the placebo group in the frequency of symptomatic or asymptomatic hemorrhage. "
07/01/1999 - "This fact, and the pronounced antiischemic effect of NXY-059, suggest that the delayed events leading to infarction may be influenced by reactions occurring at the blood-endothelial interface."
08/03/2001 - "Our preliminary data demonstrate that administration of NXY-059 (60 mg/kg/h for 24 h) ameliorates cortical infarction in rats subjected to permanent focal cerebral ischemia with 24 h survival."
08/03/2001 - "NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat."
|1.||disufenton sodium (NXY 059)
|3.||Factor VIIa (Activated Factor VII)
|6.||TNK-tissue plasminogen activator
|7.||Cytochromes c (Cytochrome c)
|9.||Tissue Plasminogen Activator (Alteplase)